// App-Quantinova.ai

BSH2020‐PO‐110 : The UK experience of daratumumab monotherapy in relapsed systemic AL amyloidosis

Researchers

Presenter

  • O. Cohen

Principal Investigators

  • M. H. Brodermann

  • I. J. Blakeney

  • S. Mahmood

  • S. Sachchithanantham

  • S. Ravichandran

  • H. Lachmann

  • C. Whelan

  • R. Shah

  • S. Cheesman

  • S. Worthington

  • P. Hawkins

  • J. Gillmore

  • A. Wechalekar

Medical Centers

  • Haematology, National Amyloidosis Centre, Royal Free Hospital

  • University College London Hospitals NHS Foundation Trust, Ibadan, Nigeria

  • Nephrology

  • Cardiology

  • Amyloidosis, National Amyloidosis Centre, Royal Free Hospital, London, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Nephrology

  • Oncology (ONC)

  • Musculoskeletal

  • Genetic Disorder

Disease

  • Orthostatic hypotension

  • Cardiorenal syndrome

  • Multiple Myeloma

  • Thrombocytopenia

  • AL Amyloidosis

  • Amyloid disease

  • Angina

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Cluster of Differentiation 38

Drug/Treatment

  • Lenalidomide

  • daratumumab Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved